Bill would eliminate costly difference between oral, IV chemotherapy

Thomas Van Hoof learned about the nuances of how some health plans cover oral chemotherapy drugs the same way most people do: He was diagnosed with cancer. The cancer was multiple myeloma, and the treatment includes Revlimid, a drug that costs roughly $120,000 a year. Revlimid is given orally, not intravenously, and the difference meant that Van Hoof's health plan would cover only half the cost. (JOURNAL SENTINEL, 1/24)